| | Identification | Back Directory |  | [Name] 
 LCL-161
 |  | [CAS] 
 1005342-46-0
 |  | [Synonyms] 
 CS-987
 LCL-161
 LCL-161; LCL161
 LCL-161 USP/EP/BP
 LCL161, inhibitor of Apoptosis Protein (IAP) family of proteins
 LCL161, 98%, inhibitor of Apoptosis Protein (IAP) family of proteins
 (S)-N-((S)-1-Cyclohexyl-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)
 N-[(1S)-1-Cyclohexyl-2-{(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]-1-pyrrolidinyl}-2-oxoethyl]-N2-MethylalaninaMide
 (2S)-N-[(1S)-1-Cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-propanamide
 N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-(2S)-propanamide
 Propanamide, N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-, (2S)-
 (2S)-N-[(1S)-1-Cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-propanamide                                             LCL 161
 |  | [Molecular Formula] 
 C26H33FN4O3S
 |  | [MDL Number] 
 MFCD23160049
 |  | [MOL File] 
 1005342-46-0.mol
 |  | [Molecular Weight] 
 500.629
 | 
 | Chemical Properties | Back Directory |  | [Boiling point ] 
 713.7±60.0 °C(Predicted)
 |  | [density ] 
 1.245±0.06 g/cm3(Predicted)
 |  | [storage temp. ] 
 Store at -20°C
 |  | [solubility ] 
 ≥25.05 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
 |  | [form ] 
 solid
 |  | [pka] 
 14.25±0.46(Predicted)
 |  | [color ] 
 White to yellow
 |  | [InChIKey] 
 UFPFGVNKHCLJJO-SSKFGXFMSA-N
 |  | [SMILES] 
 C(N[C@@H](C1CCCCC1)C(N1CCC[C@H]1C1=NC(C(=O)C2=CC=C(F)C=C2)=CS1)=O)(=O)[C@@H](NC)C
 | 
 | Hazard Information | Back Directory |  | [Description] 
 LCL-161 is a small molecule Smac mimetic that inhibits multiple inhibitor of apoptosis (IAP) family proteins.
 |  | [Uses] 
 LCL 161 is a second mitochondria-derived activator of caspases (SMAC) inhibitor used to prolong patient survival by increasing apoptosis of anti-tumor drugs.
 |  | [Synthesis] 
 
 General procedure for the synthesis of (S)-N-((S)-1-cyclohexyl-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide from B6 to B7 (Compound (I)) using Compound (CAS:1005342-82-4) as a raw material. To a 2L Argonaut reactor containing 120 g (20 mmol) of crude B6 was added 360.8 g (400 mL) of ethyl acetate. The solution was heated to 45±3°C and 109.1 g (120 mL) of isopropanol solution of 5-6N HCl was slowly added while maintaining the temperature at 45±3°C for 30 min. Stirring was continued at 45±3°C for 2 hours. Samples were taken for process control analysis. If the process control analysis passed, the reaction mixture was cooled to 18±3°C. The solution was slowly added to another 2L Argonaut reactor, which was pre-filled with 500g of water and 82.9g of potassium carbonate, while controlling the temperature at 5 ± 3°C. After stirring at 5±3°C for 30 minutes, 451 g (500 mL) of ethyl acetate was added. The solution was warmed to 20±3°C and kept for 1 hour. The two layers were separated and the upper organic phase was retained as B7 was present in this phase. The organic layer was washed with 286.6 g (250 mL) of brine and the lower aqueous phase was discarded. The upper organic phase was concentrated under reduced pressure to 500 mL at 30 °C. 1368 g (2 L) of heptane was slowly added while maintaining the temperature at 30 ± 3 °C. The suspension was cooled to 18 °C and the temperature was set at 30 ± 3 °C. The suspension was cooled to 18±3°C and held for 1 hr. The solids were collected by filtration and washed with 136 g (200 mL) of simvastatin-containing heptane. The solid was dried in an oven at 45°C for 16 hours to give 80 g of B7 in 80% yield. |  | [in vivo] 
 
 Tumor-bearing mice are treated with vehicle or LCL161 p.o. at a dose of 50 mg/kg/day, or SC-2001 p.o. at a dose of 10 mg/kg/day, 5 days a week, or in combination for the duration of the study. Tumor growth is significantly inhibited by co-treatment with SC2001 and LCL161 and tumor size in the co-treatment group is only one third of that of the control group at the end of the study[2]. LCL161 is a first-in-class oral Smac mimetic shown to induce degradation of cIAP1 and cleavage of caspase 3 in mouse xenograft models[4]. |  | [References] 
 [1] Patent: WO2011/18474,  2011,  A1. Location in patent: Page/Page column 42
 | 
 | 
                    
                        
                            | Company Name: | DKMbiochem.Co. Ltd  Gold |  
                            | Tel: | 15901859516 |  
                            | Website: | http://www.dkmbiochem.com/ |  |